错配修复缺陷之外?治疗前中性粒细胞与淋巴细胞比值与接受免疫治疗的复发性子宫内膜癌患者总生存改善相关
研究纳入2016至2021年接受免疫治疗的复发性子宫内膜癌患者106例,按治疗前中性粒细胞与淋巴细胞比值(NLR)<6(77例)或≥6(29例)分层。两组首次影像学评估缓解率无显著差异,无进展生存无差异,但NLR<6与总生存改善相关;NLR<6组一年生存概率69%(95%CI 58%,82%),NLR≥6组41%(95%CI 26%,67%)。作者认为NLR有望作为免疫治疗后生存的预测生物标志物。
要点
- 治疗前NLR<6组一年生存概率69%(95%CI 58%,82%),NLR≥6组41%(95%CI 26%,67%)。
- NLR<6与NLR≥6两组首次影像学评估缓解率无显著差异(p 0.691)。
- 按NLR<6与≥6分层的无进展生存曲线无差异,但NLR<6与总生存改善相关(p<0.05)。
核心结论
- 治疗前NLR<6与接受免疫治疗的复发性子宫内膜癌患者总生存改善相关。
- 作者认为NLR有望作为复发性子宫内膜癌患者免疫治疗后生存的预测生物标志物。
研究设计与样本
- 纳入2016至2021年接受单药或联合免疫治疗的复发性子宫内膜癌患者106例。
- 从病历获取人口学资料、治疗前实验室结果、病理数据、首次影像学评估缓解情况及肿瘤结局。
- 按NLR<6(n=77,72.6%)或NLR≥6(n=29,27.3%)分层,生成Kaplan-Meier曲线比较无进展生存和总生存。
主要发现
- 多数为子宫内膜样病理(59%),广泛转移性疾病,36.8%在开始免疫治疗前已接受≥2线治疗。
- 错配修复缺陷(dMMR)肿瘤52例(49.1%);多数dMMR患者(94.3%)接受单药帕博利珠单抗,多数错配修复正常患者(78.7%)接受仑伐替尼联合帕博利珠单抗。
- NLR<6组首次影像学评估缓解率40.2%(部分缓解29.9%,完全缓解10.4%),NLR≥6组31%(部分缓解27.5%,完全缓解3.4%),p 0.691。
- 按NLR<6与≥6分层的Kaplan-Meier曲线显示无进展生存无差异。
- NLR<6组一年生存概率69%(95%CI 58%,82%),NLR≥6组41%(95%CI 26%,67%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the association of pre-treatment neutrophil-to-lymphocyte ratio (NLR) with progression-free survival (PFS) and overall survival (OS) for patients with recurrent endometrial cancer (EC) treated with immunotherapy. METHODS: Recurrent EC patients treated with immunotherapy alone or in combination from 2016 to 2021 were included. Demographics, pre-treatment laboratory results, pathologic data, response at first radiographic assessment, and cancer outcomes were obtained from the medical record. Kaplan-Meier curves were generated to compare PFS and OS stratified by NLR. RESULTS: The 106 patients included in the study were stratified by NLR <6 (n = 77, 72.6%) or NLR ≥6 (n = 29, 27.3%). Most had endometrioid pathology (59%), widely metastatic disease, and 36.8% had received ≥2 treatment lines before initiating immunotherapy. Mismatch repair deficiency (dMMR) was noted in 52 (49.1%) tumors. Most dMMR patients (94.3%) were treated with single-agent pembrolizumab, and most MMR proficient patients (78.7%) were treated with lenvatinb plus pembrolizumab. In the overall cohort, 40.2% (partial response (PR) 29.9%, complete response (CR) 10.4%) of patients with a NLR <6 responded at first radiographic assessment, compared to 31% (PR 27.5%, CR 3.4%) of patients with NLR ≥6 (p 0.691). Kaplan-Meier curves stratified by NLR <6 vs. ≥6 showed no difference in PFS. However, NLR <6 was associated with improved OS (p < 0.05). In the NLR < 6 group, the probability of survival at one year was 69% (95% CI: 58%, 82%), compared to 41% (95% CI: 26%, 67%) for the NLR > 6 group. CONCLUSIONS: Pre-treatment NLR <6 was associated with improved OS for recurrent EC patients treated with immunotherapy. NLR holds promise as a predictive biomarker for survival after immunotherapy treatment for patients with recurrent EC.
引用
- Barrington DA, Calo C, Baek J, et al. Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy. Gynecol Oncol. 2022. PMID: 35907683. doi:10.1016/j.ygyno.2022.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。